Breaking News Instant updates and real-time market news.

TEVA

Teva

$30.76

0.06 (0.20%)

06:59
04/21/17
04/21
06:59
04/21/17
06:59

Teva risk/reward favorable at current share levels, says Citi

Citi analyst Liav Abraham views Teva's risk/reward profile as favorable at current share levels. The analyst's analysis suggests some upside to consensus FY17 generics estimates. Abraham acknowledges investor caution ahead of the new CEO announcement, and lowered her price target for the shares to $42 from $47, but she keeps a Buy rating on Teva.

  • 04

    May

  • 11

    May

  • 30

    Aug

TEVA Teva
$30.76

0.06 (0.20%)

03/07/17
JEFF
03/07/17
NO CHANGE
Target $33
JEFF
Buy
Supernus settlement modestly better than expected, says Jefferies
Jefferies analyst David Steinberg says Supernus Pharmaceuticals (SUPN) should be able maintain exclusivity on 65% of Trokendi XR sales until January 2023 following its settlement with Zydus Pharmaceutical. The analyst views the settlement as modestly better than his forecast. Should Supernus secure a similar settlement with Teva (TEVA), it would be well positioned to transition the revenue stream from its current epilepsy franchises to two late-stage pipeline candidates, Steinberg tells investors in a research note. He keeps a Buy rating on Supernus with a $33 price target.
04/06/17
OPCO
04/06/17
NO CHANGE
Target $43
OPCO
Outperform
Teva Austedo approval 'a nice incremental positive,' says Oppenheimer
Oppenheimer analyst Derek Archila notes that Teva (TEVA) received approval for Austedo for Huntington's chorea, which he sees as "a nice positive" given the company's recent challenges. Based on his review of the label and recent physician checks, the analyst believes Austedo could potentially become first-line therapy for Huntington's chorea and forecasts sales of about $600M by 2022 in this indication. Archila continues to like Teva's shares long term, though he expects they may be range-bound until a new CEO is hired, generic business stabilizes, and Allergan's (AGN) stake in Teva is resolved. He reiterates an Outperform rating and $43 price target on Teva's shares.
04/12/17
JEFF
04/12/17
NO CHANGE
Target $43
JEFF
Buy
Jefferies views Alder concerns as overblown, sees buying opportunity
After spending time with an intellectual property expert, Jefferies analyst Brian Abrahams believes IP concerns relating to Alder Biopharmaceuticals (ALDR) remain overdone. He does not believe Teva's (TEVA) patents will be upheld as valid in the U.S. Abrahams does not think IP conflicts would dissuade potential partners and/or acquirers and keeps a Buy rating on Alder with a $43 price target. The analyst sees a buying opportunity at current levels into the Phase III data.
04/12/17
LEER
04/12/17
NO CHANGE
Target $68
LEER
Outperform
Neurocrine Valbenazine approved with 'best case,' says Leerink
Following Neurocrine's (NBIX) announcement of FDA approval of Ingrezza, or valbenazine, for adults with Tardive Dyskinesia, Leerink analyst Paul Matteis says that the language in the label looks to be a best-case scenario for the company as it outlines few safety risks and does not contain a black box warning for increased risk of suicidality. The analyst believes the latter adds to valbenazine's advantages over Teva's (TEVA) SD-809. Matteis moved his odds of FDA approval from 90% to 100%, reiterated an Outperform rating on Neurocrine's stock and raised his price target on the shares to $68 from $65.

TODAY'S FREE FLY STORIES

AMD

AMD

$13.12

0.04 (0.31%)

, TSLA

Tesla

$375.10

-9.9 (-2.57%)

15:57
09/20/17
09/20
15:57
09/20/17
15:57
Periodicals
Tesla working with AMD on self-driving car AI chip, CNBC says »

Tesla (TSLA) is using AMD…

AMD

AMD

$13.12

0.04 (0.31%)

TSLA

Tesla

$375.10

-9.9 (-2.57%)

NVDA

Nvidia

$187.35

-0.2 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AMD

AMD

$13.12

0.04 (0.31%)

, TSLA

Tesla

$375.10

-9.9 (-2.57%)

15:54
09/20/17
09/20
15:54
09/20/17
15:54
Periodicals
Breaking Periodicals news story on AMD, Tesla »

Tesla working with AMD on…

AMD

AMD

$13.12

0.04 (0.31%)

TSLA

Tesla

$375.10

-9.9 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

15:50
09/20/17
09/20
15:50
09/20/17
15:50
General news
More from Yellen: »

More from Yellen: FOMC…

VIX

Volatility Index S&P 500 Options

15:40
09/20/17
09/20
15:40
09/20/17
15:40
Options
Active trading in VIX calls as players replace expiring positions »

Active trading in VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:35
09/20/17
09/20
15:35
09/20/17
15:35
General news
Yellen on the FRB »

Yellen on the FRB: she is…

DMPI

DelMar Pharmaceuticals

$1.12

0.0294 (2.70%)

15:33
09/20/17
09/20
15:33
09/20/17
15:33
Syndicate
DelMar Pharmaceuticals announces $10M registered direct offering at-the-market »

DelMar Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$47.94

0.27 (0.57%)

15:30
09/20/17
09/20
15:30
09/20/17
15:30
Options
Far downside put buying in Morgan Stanley »

Far downside put buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

  • 22

    Oct

JWN

Nordstrom

$46.13

-0.09 (-0.19%)

15:25
09/20/17
09/20
15:25
09/20/17
15:25
Conference/Events
Nordstrom management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$71.38

-1.1 (-1.52%)

15:25
09/20/17
09/20
15:25
09/20/17
15:25
Options
Bunge call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:25
09/20/17
09/20
15:25
09/20/17
15:25
General news
More from Yellen on inflation »

More from Yellen on…

WFC

Wells Fargo

$53.95

0.591 (1.11%)

15:22
09/20/17
09/20
15:22
09/20/17
15:22
Hot Stocks
Chair Yellen calls Wells Fargo actions 'unacceptable' »

Fed Chair Janet Yellen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 12

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

15:20
09/20/17
09/20
15:20
09/20/17
15:20
General news
The FOMC dot-plot projections »

The FOMC dot-plot…

$NSD

NASDAQ Market Internals

15:17
09/20/17
09/20
15:17
09/20/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

15:16
09/20/17
09/20
15:16
09/20/17
15:16
Recommendations
Alnylam analyst commentary  »

Alnylam price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

$NYE

NYSE Market Internals

15:16
09/20/17
09/20
15:16
09/20/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$170.00

4.17 (2.51%)

15:14
09/20/17
09/20
15:14
09/20/17
15:14
Conference/Events
Lennox management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

VXX

iPath S&P 500 VIX Short-Term Futures

$41.28

0.37 (0.90%)

15:10
09/20/17
09/20
15:10
09/20/17
15:10
Options
Notable put write in longer-term options on the Short-term VIX ETN »

Notable put write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:09
09/20/17
09/20
15:09
09/20/17
15:09
General news
Yellen repeats intention to serve out term as chair »

Fed Chair Yellen added…

DLPH

Delphi

$100.88

-0.02 (-0.02%)

, BBRY

BlackBerry

$9.14

-0.12 (-1.30%)

15:05
09/20/17
09/20
15:05
09/20/17
15:05
Hot Stocks
Delphi confirms autonomous driving partnership agreement with BlackBerry »

Delphi Automotive (DLPH)…

DLPH

Delphi

$100.88

-0.02 (-0.02%)

BBRY

BlackBerry

$9.14

-0.12 (-1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UAA

Under Armour

$16.43

-0.38 (-2.26%)

15:00
09/20/17
09/20
15:00
09/20/17
15:00
Options
Under Armour attracts a bullish option play as the slide in shares continues »

Under Armour attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

14:55
09/20/17
09/20
14:55
09/20/17
14:55
General news
Fed Chair Yellen reiterated the FOMC statement »

Fed Chair Yellen…

MLHR

Herman Miller

$34.95

0.1 (0.29%)

14:49
09/20/17
09/20
14:49
09/20/17
14:49
Options
Herman Miller options imply 9.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

SPX

S&P 500

14:47
09/20/17
09/20
14:47
09/20/17
14:47
General news
Yellen says Fed has commitment to raising inflation to 2% »

Federal Reserve Chair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHD

Church & Dwight

$49.66

-0.91 (-1.80%)

14:47
09/20/17
09/20
14:47
09/20/17
14:47
Syndicate
Breaking Syndicate news story on Church & Dwight »

Church & Dwight files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 07

    Nov

CSBR

Champions Oncology

$3.38

-0.21 (-5.85%)

14:45
09/20/17
09/20
14:45
09/20/17
14:45
Hot Stocks
Champions Oncology receives $2M contract from HHS contract 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.